Republican Senator Rand Paul (R-KY) has accused House Speaker Nancy Pelosi (D-CA) of receiving monoclonal antibodies as a treatment for COVID-19 after Democrats blocked the public from accessing those therapies.
Speaking during an interview on Fox News with Sean Hannity, Sen. Paul blasted Pelosi and President Joe Biden’s administration for a double standard on the treatments.
Paul said he believes Pelosi was treated with monoclonal antibodies and says the American people deserve to know why they are blocked from accessing the same treatments.
He also suggested that President Biden may have also been treated with the same therapy after coming into close contact with Pelosi on the day before she tested positive for the virus.
“What’s even worse than that it’s not just production which is controlled by the government,” Paul told Hannity.
“It’s also the fact that they’ve actually withdrawn the Sotrovimab.
“They withdrew it because they say it’s not working in the laboratory, but thousands of doctors across the country are saying — well, it still appears to be working in the clinical practice.
“See, this happened in January,” Paul noted.
“They withdrew the first two monoclonals because they said they weren’t working in the lab.
“Meanwhile, thousands of doctors were left with no treatment, and they were saying we think it still works.”
“So this is what’s going on now, and this is why it’s going to be a very important question for Nancy Pelosi,” Paul continued.
“Did she receive the monoclonal?
“And so, if they’ve removed them from the market for the rest of the hoi polloi, but Nancy Pelosi gets them, or President Biden should get the monoclonals, then we’ve got a real, real problem that there’s a different standard for Democrat politicians than the regular public.”
“I think they should leave them out there and should be developing new monoclonal antibodies,” he added.
“But the thing is, is there still is some omicron. Just because most of the virus is the new variant doesn’t mean that the monoclonal antibodies may not work against the residual omicron, but also might have some carryover effect to this variant as well.
“I think it’s premature to remove them from the market, but that’s what happens when you centralize all the medical decision-making in Washington, which is a terrible mistake.”